What this means
This study is a trial that has not reported results yet. It will test whether ALA, a fat found in some plants, helps thinking and blood vessels in the brain.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 60 and over
- Where
- 1 site, including New Jersey
The science
- Registered title
- ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
- Trial ID
- NCT07392723 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
- What is tested
- Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
- Sponsor
- Michal Schnaider Beeri, Ph.D.
- Ages
- 60 Years to no maximum
- Dates
- First posted Feb 6, 2026 · updated Feb 6, 2026
Registry summary
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. This innovative approach offers a safe, cost-effective, and easily implementable therapeutic strategy for older adults at high risk for Alzheimer's dementia, especially APOE4 carriers, addressing a critical need given the limited cognitive benefits and significant adverse events of current amyloid-clearing drugs in this population.
Sites (1)
- Rutgers - Institute for Health, New Brunswick, New Jersey, United States